Aapro, Matti <br/><br/>
Randomized phase II study evaluating weekly oral vinorelbine versus weekly paclitaxel in estrogen receptor-positive, HER2-negative patients with advanced breast cancer (NorBreast-231 trial).  [electronic resource] 

 -  Breast (Edinburgh, Scotland)  Jun 2019 
 - 7-14 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial 
<br/><br/><label>ISSN: </label>1532-3080 
<br/><br/><label>Standard No.: </label>10.1016/j.breast.2019.01.009  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Agents, Phytogenic--administration & dosage<br/>Breast Neoplasms--drug therapy<br/>Drug Administration Schedule<br/>Female<br/>Humans<br/>Middle Aged<br/>Paclitaxel--administration & dosage<br/>Receptor, ErbB-2--metabolism<br/>Receptors, Estrogen--metabolism<br/>Treatment Outcome<br/>Vinorelbine--administration & dosage